Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 41,900 shares, a growth of 37.8% from the March 31st total of 30,400 shares. Based on an average trading volume of 46,700 shares, the short-interest ratio is currently 0.9 days.
Separately, StockNews.com initiated coverage on Tenax Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.
TENX traded up $0.08 during trading on Friday, hitting $0.73. The company’s stock had a trading volume of 28,632 shares, compared to its average volume of 37,886. Tenax Therapeutics has a twelve month low of $0.50 and a twelve month high of $2.30. The stock’s fifty day moving average price is $0.66 and its 200-day moving average price is $0.95.
About Tenax Therapeutics (Get Rating)
Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
- Get a free copy of the StockNews.com research report on Tenax Therapeutics (TENX)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.